The US prenatal diagnostics market is one of the largest markets in the world for fetal monitoring, diagnostics, and predictive testing. It consists of a series of physician prescribed tests for monitoring maternal and fetal health. The current invasive technologies such as CVS and amniocentesis that are used to detect chromosomal abnormalities pose serious risks of miscarriages and are being replaced by the non-invasive prenatal diagnostics technologies.

Although NIPD is a relatively nascent segment of the prenatal diagnostics, it presents a lucrative growth potential to industry participants. The segment is mainly supported by rising incidences of fetal health-related abnormalities and the urgent need for safe, accurate and early diagnosis. Products such as MaterniT21 Plus, Verifi, and Harmony prenatal tests are the current tests available in the market. Around 100,000 samples were likely tested by MaterniT21 plus test alone by the first quarter of 2013 since its launch.

Further the report “US Non-Invasive Prenatal Diagnostics - Market Insight”, provides a transparent view on the present regulatory framework elaborating on the existing loopholes. A thorough analysis has been done illustrating the views of regulatory authorities, players and consumers towards the regulatory stringency, and the direction of regulations in the future have also been covered.

Currently, the US NIPD sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These companies are effectively taking steps to promote their LDTs among the US population especially targeting physicians to recommend their products. In future, the launch of Natera’s test is expected to impact the market significantly, thereby boosting the potential size and sample volume.

The report, which provides a prudent analysis on the current and future size of the market weighing the possible pessimistic and optimistic scenarios, is a must buy for new market entrants in the diagnostics field, planning to enter the prenatal segment.

Table Of Contents

US Non-Invasive Prenatal Diagnostics - Market Insight
1. Analyst View
2. Research Methodology
3. Statistical Snapshot - Pregnancies and Chromosomal Abnormalities
4. Overview of US Prenatal Diagnostics Market
4.1 Introduction
4.2 Prenatal Diagnostics Industry
4.2.1 Preliminary Prenatal Testing
4.2.2 First Trimester Screening
4.2.3 Second Trimester Screening
4.2.4 Chorionic Villus Sampling (CVS) Testing
4.2.5 Amniocentesis Testing
5. US Non-Invasive Prenatal Diagnostics - Market Insight
5.1 Tests Available in the Market
5.1.1 MaterniT21 (Sequenom)
5.1.2 Verifi (Verinata Health)
5.1.3 Harmony Prenatal Test (Ariosa Diagnostics)
5.1.4 Panorama (Natera)
5.2 Current and Future Market Projections to 2017
5.3 Regulatory Insight
5.3.1 Current Regulatory Scenario
5.3.2 Regulatory Authority Perspective
5.3.3 Diagnostic Test Provider Perspective
5.3.4 Consumers' Perspective
5.3.5 Analyst Inputs
6. Current Technologies in the Market
7. Constraints in NIPD Market
8. Competitive Assessment
8.1 Ariosa Diagnostics
8.1.1 Company Overview
8.1.2 Product Overview
8.1.3 Strengths and Weaknesses
8.2 Sequenom
8.2.1 Company Overview
8.2.2 Product Overview
8.2.3 Strengths and Weaknesses
8.3 Verinata
8.3.1 Company Overview
8.3.2 Product Overview
8.3.3 Strengths and Weaknesses
8.4 Natera
8.4.1 Company Overview
8.4.2 Product Overview
8.4.3 Strengths and Weaknesses

List of Figures:

Figure 3-1: Population Base (Million), 2000-2010
Figure 4-1: Prenatal Testing Market (Billion US$), 2012-2016
Figure 4-2: Preliminary Prenatal Testing Market (Million US$), 2012-2016
Figure 4-3: First Trimester Screening Market (Million US$), 2012-2016
Figure 4-4: Second Trimester Screening Market (Million US$), 2012-2016
Figure 4-5: CVS Testing Market (Million US$), 2012-2016
Figure 4-6: Amniocentesis Testing Market (Million US$), 2012-2016
Figure 5-1: Non-Invasive Prenatal Diagnostics Market (Million US$), 2012-2017
Figure 5-2: Share of Players in Number of NIPD Tests Performed (2012)
Figure 5-3: Share of Players in NIPD Market (2012)
Figure 5-4: Forecast for Share of Players in Number of NIPD Tests Performed (2017)
Figure 5-5: Forecast for Share of Players in NIPD Market (2017)
Figure 5-6: Laboratorians' Attitudes towards FDAs Regulations on Lab Developed Tests (LDT)

List of Tables:

Table 3-1: Number of Births and Abortions (2000-2010)
Table 3-2: Number of Multiple Pregnancies (2000-2009)
Table 3-3: Prevalence of Chromosomal Abnormalities
Table 4-1: Major Preliminary Prenatal Tests Performed
Table 4-2: Major First Trimester Screening Tests Performed
Table 4-3: Major Second Trimester Screening Tests Performed
Table 5-1: Inter-comparison of CLIA and FDA Regulatory Pathway
Table 6-1: Common Commercial Kits and Protocols for Isolation of ccff DNA from Maternal Plasma

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

2015 Current and Emerging Suppliers Of Immunodiagnostic, Microbiology, Cancer Diagnostic, Molecular Diagnostic, Hematology, Coagulation and Blood Banking Instruments and Reagents

2015 Current and Emerging Suppliers Of Immunodiagnostic, Microbiology, Cancer Diagnostic, Molecular Diagnostic, Hematology, Coagulation and Blood Banking Instruments and Reagents

  • $ 8 500
  • Industry report
  • February 2015
  • by Venture Planning Group

This new report from VPGMarketResearch.com provides analyses of current and emerging suppliers of immunodiagnositc, microbiology, cancer diagnostic, molecular diagnostic, hematology, coagulation and blood ...

Fetal Monitoring, Diagnostics and Predictive Tests

Fetal Monitoring, Diagnostics and Predictive Tests

  • $ 6 650
  • Industry report
  • January 2015
  • by BCC Research

REPORT HIGHLIGHTS The global market for fetal monitoring, prenatal diagnostics, predictive tests and neonatal monitoring was valued at roughly $8.6 billion in 2013 and about $9.0 billion in 2014. This ...

The US Blood Transfusion Diagnostics Market : Effective Strategies for Vendors to Tackle the Decrease in Blood Supply Demand

The US Blood Transfusion Diagnostics Market : Effective Strategies for Vendors to Tackle the Decrease in Blood Supply Demand

  • $ 6 500
  • Industry report
  • March 2015
  • by Frost & Sullivan

Methodology The majority of the quantitative and qualitative information contained in this research service was acquired through primary research conducted with blood banking product providers. Most consultations ...


Download Unlimited Documents from Trusted Public Sources

Global Pathology Description

  • March 2015
    69 pages
  • Diabetes Mellit...  

    Diagnostic  

    In Vitro Instru...  

  • Australia  

View report >

Antigen Industry in Africa - Forecast

  • March 2015
    8 pages
  • Antigen  

    Rapid Test  

    in Vitro Diagno...  

  • Africa  

View report >

Diagnostics Industry in the UK and the US - Forecast

  • March 2015
    2 pages
  • Diagnostics  

  • United Kingdom  

    United States  

View report >

Related Market Segments :

Diagnostics
DNA

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.